Skip to content
Pyrimethamine
Daraprim, Fansidar (pyrimethamine) is a small molecule pharmaceutical. Pyrimethamine was first approved as Daraprim on 1982-01-01. It is used to treat aids-related opportunistic infections, falciparum malaria, malaria, and toxoplasmosis in the USA. It is known to target multidrug and toxin extrusion protein 1 and multidrug and toxin extrusion protein 2.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
immune system diseasesD007154
Trade Name
FDA
EMA
Daraprim (generic drugs available since 2020-02-28)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Pyrimethamine
Tradename
Company
Number
Date
Products
DARAPRIMVyera PharmaceuticalsN-008578 RX1982-01-01
1 products, RLD, RS
Pyrimethamine
+
Sulfadoxine
Tradename
Company
Number
Date
Products
FANSIDARRocheN-018557 DISCN1982-01-01
1 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
daraprimNew Drug Application2017-08-31
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
aids-related opportunistic infections—D017088—
falciparum malariaEFO_0007444D016778B50
malariaEFO_0001068D008288B54
toxoplasmosisEFO_0007517D014123B58
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
P: Antiparasitic products, insecticides and repellents
— P01: Antiprotozoals
— P01B: Antimalarials
— P01BD: Diaminopyrimidines, antimalarials
— P01BD01: Pyrimethamine
— P01BD51: Pyrimethamine, combinations
— P01BF: Artemisinin and derivatives, combinations
— P01BF04: Artesunate, sulfalene and pyrimethamine
— P01BF09: Artesunate, sulfadoxine and pyrimethamine
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePYRIMETHAMINE
INNpyrimethamine
Description
Pyrimethamine is an aminopyrimidine that is pyrimidine-2,4-diamine which is substituted at position 5 by a p-chlorophenyl group and at position 6 by an ethyl group. It is a folic acid antagonist used as an antimalarial or with a sulfonamide to treat toxoplasmosis. It has a role as an antimalarial, an EC 1.5.1.3 (dihydrofolate reductase) inhibitor and an antiprotozoal drug. It is an aminopyrimidine and a member of monochlorobenzenes.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1
Identifiers
PDB7OPJ
CAS-ID58-14-0
RxCUI9010
ChEMBL IDCHEMBL36
ChEBI ID8673
PubChem CID4993
DrugBankDB00205
UNII IDZ3614QOX8W (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
SLC47A1
SLC47A1
SLC47A2
SLC47A2
Organism
Homo sapiens
Gene name
SLC47A1
Gene synonyms
MATE1
NCBI Gene ID
55244
Protein name
multidrug and toxin extrusion protein 1
Protein synonyms
hMATE-1, MATE-1, multidrug and toxin extrusion 1, solute carrier family 47 (multidrug and toxin extrusion), member 1, Solute carrier family 47 member 1
Uniprot ID
Q9NVA3
Mouse ortholog
—
—
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 14,394 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
147 adverse events reported
View more details